Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NV01-A02

Next Previous
Drug Profile

NV01-A02

Alternative Names: NV01 A02

Latest Information Update: 31 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuroventi
  • Class Behavioural disorder therapies; Small molecules
  • Mechanism of Action Neurotransmitter receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pervasive child development disorders
  • Clinical Phase Unknown Fragile X syndrome

Most Recent Events

  • 09 May 2025 As of May 2025, Neuroventi has patent protection for NV01-A02 for the treatment of autism spectrum disorder in South Korea, the US, the European Union, China, Japan and other countries worldwide (prior to May 2025) (Neuroventi pipeline, May 2025)
  • 09 May 2025 As of May 2025, Neuroventi has patent protection for NV01-A02 for the treatment of fragile X syndrome in South Korea, the US, the European Union, China, Japan and other countries worldwide (prior to May 2025) (Neuroventi pipeline, May 2025)
  • 01 Apr 2025 Phase-II clinical trials in Pervasive child development disorders (In children, In adolescents) in South Korea (PO) (NCT06951854)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top